IMV Inc. (IMV.TO)
| Previous Close | 1.1200 |
| Open | 1.1300 |
| Bid | 0.7000 x 0 |
| Ask | 0.7000 x 0 |
| Day's Range | 1.0700 - 1.1300 |
| 52 Week Range | 0.6200 - 9.0000 |
| Volume | |
| Avg. Volume | 0 |
| Market Cap | 13.117M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | Sept 26, 2023 - Sept 30, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 37.40 |
Business WireIMV Accepts an Offer from its Secured Lenders for the Sale of its Intellectual Property Assets
DARTMOUTH, Nova Scotia, September 01, 2023--IMV Inc. (the "Company" or "IMV") announces today that it has accepted an offer (the "Offer") from IMV’s largest secured creditors (the "Secured Lenders"), pursuant to which IMV and its subsidiary, Immunovaccine Technologies Inc. have agreed to sell to the Secured Lenders its intellectual property assets (the "Transaction") in consideration for a partial reduction of debt owing to the Secured Lenders.
Business WireIMV Inc. Announces Update on CCAA Proceedings and Sales and Investment Solicitation Process
DARTMOUTH, Nova Scotia, July 26, 2023--IMV Inc. (the "Company" or "IMV"), recently announced an update on the Sales and Investment Solicitation Process (the "SISP") implemented as part of its ongoing proceedings under the Companies' Creditors Arrangement Act (the "CCAA").
Business WireIMV Receives NASDAQ Delisting Notice
DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass., May 08, 2023--IMV Inc. (the "Company" or "IMV") (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today announced that it was notified by the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") that Nasdaq, in accordance with Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1, has in exerci
